<DOC>
	<DOCNO>NCT01386684</DOCNO>
	<brief_summary>The purpose study evaluate Canadian Real Life Evaluation Effectiveness Lupron Management Prostate Cancer .</brief_summary>
	<brief_title>Real Life Evaluation Lupron Management Prostate Cancer : A Canadian Post Marketing Observational Study</brief_title>
	<detailed_description>This Canadian Post Marketing Observational Study utilize prospective cohort design . Patients Prostate Cancer prescribe Lupron enter study cohort follow maximum 36 month recommend assessment 3 , 6 , 12 , 18 , 24 , 30 36 month baseline . Treatment patient follow accord physician 's judgment , regional regulation product monograph .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>. Has provide write informed consent allow use data study provide permission contact study personnel ii . Diagnosed Prostate Cancer iii . Prescribed Lupron part treatment treat physician . Currently participate another prospective study include control clinical trial observational study . â€¢ Exclusion patient participate observational study necessary order prevent overrepresentation specific patient different study , practical consideration regard authority utilize patient 's data statistical issue relate lack independence observation different study trigger multiplicity issue ii . Patient sign inform consent iii . Survival expectancy le 23 year per treat physician 's judgment iv . Presence condition , opinion treat physician , prohibits patient participate study obscures assessment treatment Prostate Cancer v. History alcohol drug abuse vi . No longer 6 month therapy currently luteinizing hormonereleasing hormone ( LHRH ) treatment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
</DOC>